Management of Symptomatic Uterine Fibroids in Pregnancy by Laparotomic Myomectomy: a Prospective Cohort Study
LPTM-UFs-P
1 other identifier
observational
28
1 country
1
Brief Summary
The frequency of women presenting with a combination of uterine fibroids and pregnancy is in-creasing nowadays. Uterine fibroids in pregnancy are an unfavorable condition in themselves and being reactive to hormonal stimuli, tending to grow, can generate symptoms of different lev-els of severity. Obstetrics and gynecologists are increasingly faced with the problem of clarifying the management tactics of pregnant patients with symptomatic fibroids, who may see their preg-nancy put at risk by these masses.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 19, 2023
CompletedStudy Start
First participant enrolled
August 19, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 19, 2023
CompletedFirst Posted
Study publicly available on registry
August 24, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2024
CompletedAugust 24, 2023
August 1, 2023
Same day
August 19, 2023
August 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
continuation of pregnancy
Pregnancy continuation after surgery.
5 months
Secondary Outcomes (1)
Fetal outcome
5 months
Interventions
Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access
Eligibility Criteria
pregnant women with symptomatic uterine fibroids (UFs)
You may qualify if:
- The large and giant size of UFs, which prevent the proper continuation of pregnancy and/or occupy the entire small and large pelvis, as well as invade and/or occupy the abdominal cavity.
- Circulatory disorders, evidenced by necrosis of the UFs.
- Atypical localization of UFs (cervical, isthmic, intraligamentary, etc.), which caused pelvic organ dysfunction (dysuric phenomena, tenesmus, impediment to the act of defecation, pelvic pain).
You may not qualify if:
- Refusal of LPTM by the patient.
- Absence of urgent indication for LPTM during pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
State-Funded Health Care Facility of Moscow Region (GBUZ MO MONIIAG)
Moscow, 101000, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrea Etrusco, M.D.
University of Palermo
- STUDY DIRECTOR
Antonio Simone Laganà, M.D. Ph.D.
University of Palermo
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.
Study Record Dates
First Submitted
August 19, 2023
First Posted
August 24, 2023
Study Start
August 19, 2023
Primary Completion
August 19, 2023
Study Completion
January 1, 2024
Last Updated
August 24, 2023
Record last verified: 2023-08